Feedback PLC TexRAD Update (5406G)
November 23 2015 - 2:00AM
UK Regulatory
TIDMFDBK
RNS Number : 5406G
Feedback PLC
23 November 2015
23 November 2015
Feedback plc
("Feedback" or the "Company")
TexRAD Update
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce that it has signed a Memorandum of
Understanding with Alliance Medical Group ("Alliance") with the
intention of integrating Feedback's TexRAD texture analysis
software into Alliance's lung cancer imaging service. Although the
technical discussions are at a very early stage, this is considered
by Feedback to be potentially of great significance as regards the
future commercialization of TexRAD software. Alliance and Feedback
plan to undertake a multi-centre imaging research study to assess
the use of TexRAD in lung cancer, with the eventual aim of gaining
National Institute for Health and Care Excellence ("NICE") approval
for TexRAD to be used in the Lung Cancer pathway. An update on the
progress of the technical discussions will be provided with
Feedback's interim results announcement in February 2016.
In January 2015, NHS England selected a collaborative network
led by Alliance to provide PET-CT scanning services across 30
locations in England following a competitive tender process. By
December 2015 Alliance and its partners in the network will be
providing a substantial amount of PET-CT imaging service in
England. Published research studies have suggested that assessing
patients already diagnosed with lung cancer by using TexRAD texture
analysis software applied on the staging PET-CT imaging examination
could potentially be a major application for TexRAD and provide
valuable information to clinicians. In April 2015, Feedback
announced a clinical adoption study was being commenced to assess
the potential for TexRAD's use in a multi-disciplinary team setting
specifically focused on non-small cell lung cancer. This was
followed in October 2015 by the announcement that the research arm
of NHS England had 'alerted' on the potential application of TexRAD
in assessing patients with lung cancer.
Dr. Balaji Ganeshan, CEO of TexRAD Ltd and Director of New
Business at Feedback Plc commented:
"We are delighted to be working with Alliance who are Europe's
leading independent provider of imaging services. The planned
research study in lung cancer will be an important step towards the
future commercialization of TexRAD."
Charles Niehaus, Group CMO, COO, Alliance Medical Group
commented:
"Alliance and clinicians of the Collaborative Network are
excited to be working with Feedback Plc to integrate the TexRAD
software within Alliance's lung cancer service across the imaging
network. We anticipate this will enhance lung cancer diagnosis and
prognosis within the NHS leading to improved patient management and
valuable information for both Alliance and Feedback."
For further information contact:
Feedback plc Tel: 01954 718072
Trevor Brown / Tom Charlton /
Balaji Ganeshan
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd Tel: 020 7469
(Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
is readily visible to the naked eye. Research to date has shown
that TexRAD could potentially assist the clinician (as an 'Imaging
Biomarker') in confident decision-making: it has the potential to
assess the prognosis, disease-severity (e.g. risk of metastases)
and response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'. TexRAD is
manufactured under licence by company Cambridge Computed Imaging
Ltd, a subsidiary of Feedback plc. More information is available on
www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQLLFLEFFLFBQ
(END) Dow Jones Newswires
November 23, 2015 02:00 ET (07:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024